AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
OSE Immunotherapeutics Highlights Advancements and Provides 2024 Outlook
OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRP? Monoclonal Antibody
OSE Immunotherapeutics Presents First Positive Clinical Results With its anti-PD1 OSE-279 in Advanced Solid Tumors
OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that the trial’s Independent Drug Safety Monitoring Board (DSMB) provided a positive recommendation on the continuation until its completion of the Phase 2 clinical trial of IL-7 Receptor (IL-7R) antagonist Lusvertikimab (OSE-127) in ulcerative colitis.
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the United States Patent and Trademark Office has granted a new patent protecting Tedopi®, a therapeutic cancer vaccine treating HLA-A2 positive patients after secondary resistance to PD-1/PD-L1 immune checkpoint inhibitor treatment. The new patent further improves the unique value proposition of Tedopi® and provides protection until year 2037 in the US.
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics Europe 2023 Conference in Amsterdam, Netherlands (June 7), at the FOCIS 2023 Annual Meeting (June 20-23), the 4th Annual Cytokine-Based Drug Development Summit 2023 (June 27-29) and at the 3rd Annual Tumor Myeloid-directed Therapies Summit 2023 (July 18-20) in Boston, US. The communications feature the latest research on pre-IND programs for BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7), CLEC-1(1) (new myeloid immune checkpoint) in immuno-oncology and for OSE-230 (first pro-resolutive monoclonal antibody) in chronic inflammation.
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented a poster and a publication in abstract book featuring Tedopi®, an immunotherapy activating tumor specific T-cells, in non-small cell lung cancer (NSCLC) and in ovarian cancer at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2 - 6.
OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies